ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration’s (FDA) approval of Incyte’s Biologics License Application (BLA) for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte. ZYNYZ, a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), was previously developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.





Whenever someone asks about dreams, there is an underlying expectation that it is something that springs up on you at a nascent age, like an epiphany where you’ve realised your life’s calling. But that is not always the case. For me, founding a global biotechnology company was not an overnight phenomenon, but a dream that gradually materialised as I started helping at my family’s pharmacy when I was eight.

